Saluja Features Newest Melanoma Detection Device

By  //  December 22, 2012

Share on Facebook Share on Twitter Share on LinkedIn Share on Delicious Digg This Stumble This


BREVARD COUNTY, MELBOURNE, FLORIDA – Anita Saluja, MD, of MIMA Dermatology, has acquired the latest technology to detect melanoma – the most dangerous type of skin cancer and the leading cause of death from skin disease.

Dr. Saluja

MelaFind® is a highly sophisticated dermatologic analysis system that dermatologists can use when deciding whether or not to remove an irregular-looking mole that they think could possibly be melanoma.

“We are excited to have this tool in our practice as a clinically validated, objective system to help us in deciding whether or not to biopsy atypical moles we see on our patients,” said Dr. Saluja.

“Everyone is at risk for melanoma. It is important for highly-trained dermatologists to have a device such as MelaFind to help us detect potential melanomas at the earliest, curable stage.”

Approved By U.S. Food and Drug Administration

MelaFind collects information from 2.5 mm deep into the skin painlessly and non-invasively using computer vision technology. MelaFind’s safety and effectiveness were proven in the largest clinical trial in melanoma detection ever conducted and has been approved by the U.S. Food and Drug Administration. In addition, MelaFind has received CE Mark approval and is approved for use in Europe.

MelaFind Listed On Cleveland Clinic’s Top 10 Innovations for 2013

“At MELA Sciences we are dedicated to dermatology and saving lives,” said the company’s website,

The Hand-Held component of MelaFind®, used to capture multi-spectral data from beneath the surface of lesions, is made up of an illuminator that shines light of 10 different specific wavelengths, including near infrared bands, a lens system composed of nine elements that creates multi-spectral data of the light scattered back from the lesions and a photon (light) sensor. ( image)

“Our mission is to develop breakthrough medical technologies to improve melanoma detection and achieve better outcomes. We see a world in which our pioneering innovations will change the way patients think about melanoma, while providing dermatologists and clinicians with new, effective, non-invasive tools to detect this dangerous condition. With these goals in mind, we have developed MelaFind®.”

Dr. Saluja is a board certified dermatologist who has been practicing in Brevard County since 2001. She earned her medical degree from The University of Michigan and received three years of dermatology specialty training at Emory University in Atlanta, GA, helping her become an expert dedicated to skin. Additionally, she is board-certified in dermatology by the American Board of Dermatology.

To contact Dr. Saluja e-mail or call 321-757-5141.

CLICK HERE TO Follow Dr. Saluja on Facebook